Mark Wilterding is recorded as CFO at RxSight, Inc. (RXST). The newest filing on record that lists Mark Wilterding as CFO at RxSight, Inc. (RXST) is dated April 28, 2026. RxSight, Inc. reported in an 8-K filed January 12, 2026 that Mark Wilterding was appointed Chief Financial Officer (and principal financial and accounting officer), effective January 11, 2026. Mark Wilterding has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for RxSight, Inc. on August 5, 2026. RxSight, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at RxSight, Inc. includes Aziz Mottiwala (CEO and Board Member), Ron Kurtz (CEO and Board Member), Ilya Goldshleger (COO) and 3 others.
“On December 13, 2025, the Company appointed Mark Wilterding as its Chief Financial Officer (and principal financial and accounting officer), effective January 11, 2026 (the "Effective Date"), replacing Shelley Thunen in such capacities.”
RxSight, Inc. Form 8-K, filed January 12, 2026
· Read the filing
Mark Wilterding on recent calls
“Consistent with the revenue range we pre-announced last month, second quarter total company revenue was $33.7 million including $6.5 million recognized in connection with our strategic collaboration agreement with Alcon.”
“As outlined in our pre-announcement press release last night, second quarter total company revenue is expected to be approximately $32 to $34 million, including $5 to $7 million related to the RxSite-Alcon Strategic Collaboration Agreement.”
“I think what was the most encouraging from our perspective was the stability we saw in LAL sales. And so that's something we've been looking for for the last several quarters. and we saw some signs of that, both in the unit volumes themselves, but also in the utilization rates.”
“Q1 sales of $30.9 million dollars declined 18 percent reflecting a year-over-year step down in ldd unit volumes consistent with expectations during the quarter we sold 20 ldds which accounted for approximately two million dollars of quarterly sales we exited the quarter with an installed base of 1 154 ldd units q1 lal…”
“Consistent with our January pre-announcement, RxCite reported fourth quarter 2025 sales of $32.6 million, down 19% year-over-year due to lower LDD sales. As you recall, we had record levels of LDD placements in the year-ago period, totaling 83 units globally, accounting for $11 million of sales.”
